Endocrinology

Ideal practice for personalized treatment of patients with type 2 diabetes

Video interview

Ideal practice for personalized treatment of patients with type 2 diabetes

E-learning Modules

Launch: 15 May 2024

Overview

In most established healthcare systems, existing individualized interventions are demonstrably effective and can halve the risk of progression from pre-diabetes to type 2 diabetes [Wareham, 2022; Valabhji, 2020; Ely, 2017]. Patients with type 2 diabetes should be at the center of care, with their preferences, values, social determinants of health, barriers to care, comorbid conditions, degree of hyperglycemia, risks of complications and susceptibility to medication side-effects considered in their treatment [Davies, 2022].

Personalization in the West could be expanded through enhanced identification of those at high risk of hyperglycemia, the division of type 2 diabetes into specific subgroups and individualization of the behavioral targets for preventative action [Wareham, 2022]. Dividing patients with type 2 diabetes into subgroups aiming to link prevalences for different diabetic complications to different subgroups, ultimately to help improve targeted prevention and treatment has been reported, [Ahlqvist, 2018; Zaharia, 2019]: Results are promising, but further research is needed.

This video interview will also highlight the importance of language in communication as part of the personalized management between healthcare professionals and those with type 2 diabetes, which has recently been recognized, in a joint ADA/EASD consensus report recommending a person-centered approach for patients which encourages their collaboration and is respectful and inclusive, [Davies, 2022].

Learning Objectives

After listening to this video interview, participants will be able to:

Target Audience

Clinicians involved in endocrinology, particularly diabetes, pre-diabetes; fertility and pregnancy management, obesity management and general practice; some content of interest to midwives and nurses involved in pre-natal and post-natal care; some content of interest to vascular specialists and podiatrists.

Language

The official language of this educational programme will be English. Simultaneous translation into Spanish and Chinese will be provided.

Faculty

Osama Hamdy

Osama Hamdy

USA

Sign up for the module

Final Programme

Download Final Programme

· Martin O. Savage ·

Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.  His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 61 countries and has published 472 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.

· Osama Hamdy ·

Osama Hamdy, MD, PhD is a world expert and recognized thought leader in obesity, nutrition, and diabetes technology. Dr. Hamdy is a senior endocrinologist and Medical Director of the Joslin Obesity Clinical Program and Director of the International Medical Affairs at Joslin Diabetes Center, and Associate Professor of Medicine at Harvard Medical School. Dr. Hamdy is very active in nutrition and obesity clinical research. His lab led to many innovations and discoveries that changed how we currently manage obesity in patients with either type 2 or type 1 diabetes and were incorporated in National and International Guidelines.

Dr. Hamdy research led to the first landmark discovery that 7% weight loss in obese patients with and without diabetes significantly improve vascular endothelial function, insulin sensitivity and markers of inflammation. Dr. Hamdy was a co-investigator in two US landmark studies: the “Diabetes Prevention Program” and “the Look AHEAD Study”. In 2005, Dr. Hamdy founded the “Weight Achievement and Intensive Treatment (Why WAIT) program, which is currently implemented nationally and internationally. He also found the Diabetes Remission Outcome Program (DROP) that helped newly diagnosed patients with diabetes within 5 years to get remission from the disease and stop medications. Dr. Hamdy co-chaired the task force that developed the global transcultural Diabetes Nutrition Algorithm (tDNA). Dr. Hamdy long-term work on diabetes technology including AID, CGMs, and AI ranked him the world’s 3rd most cited physician on diabetes technology.

Dr. Hamdy joined Joslin Diabetes Center in 1998, where he founded the obesity clinical program and restructured the inpatient diabetes program.  Dr. Hamdy won the 2015 Michaela Modan Award of the American Diabetes Association for his research on long-term diabetes weight management. He was given the Compassionate Caregiver Award of the Kenneth Schwartz Center. Dr. Hamdy has more than 150 peer-reviewed original articles, reviews, and book chapters. He is also the author of the Harvard Health Publication “The Diabetes Breakthrough” reversing diabetes through weight management. He is on the editorial review board of many medical journals including Lancet, JAMA, British Medical Journal, Diabetes Care and 2 times section editor of Nutrients and Current Diabetes Report and also associate editor of Frontiers in Nutrition.